Consistent Molecular Subtypes in Systemic Lupus Erythematosus Correlate With Disease Activity, Serological Profiles, and Unique Longitudinal Patterns
By
Loqmane Seridi
Eugene Myshkin
Erika Noss
Sheng Gao
Julio Molineros
Carolyn Cuff
Dawn Waterworth
Matthew J. Loza
July 1, 2026
Clinical Scorecard: Consistent Molecular Subtypes in Systemic Lupus Erythematosus Correlate With Disease Activity, Serological Profiles, and Unique Longitudinal Patterns
At a Glance
Category Detail
Condition Systemic Lupus Erythematosus Key Mechanisms Molecular stratification, interferon signaling, B cell/plasmablast activation Target Population Patients with active SLE (SLEDAI ≥ 6) Care Setting Clinical trials and observational studies
Key Highlights
Identification of robust molecular subtypes in SLE using large cohorts Correlation of IFN signatures with disease activity and renal involvement B cell/plasmablast programs associated with serologic activity Use of serum proteomics to capture inflammatory pathways Need for larger multicohort studies to validate findings Guideline-Based Recommendations
Diagnosis
Utilize SLEDAI score for screening and assessing disease activity Management
Consider B cell-targeted therapies such as rituximab for treatment Monitoring & Follow-up
Assess molecular subtypes and serological profiles for disease activity Risks
Potential for heterogeneous manifestations complicating treatment selection Patient & Prescribing Data
Patients aged 16 to 75 years with active SLE
Ustekinumab evaluated in phase 2 and phase 3 trials
Clinical Best Practices
Leverage whole-blood transcriptomic studies for patient subtyping Incorporate serum proteomics alongside transcriptomics for comprehensive assessment Ensure reproducibility of findings across different cohorts and platforms Related Resources & Content
